Filtered By:
Specialty: Hematology
Condition: Bleeding
Cancer: Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach
ConclusionNo signal of DDIs between DOACs and antineoplastic agents was detected, except for DOAC-neratinib. Most DDIs between DOACs and antineoplastic agents may not be clinically relevant. The DDIs between DOACs and neratinib should be further examined in future research.
Source: Journal of Thrombosis and Thrombolysis - August 10, 2023 Category: Hematology Source Type: research

Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment
Semin Thromb Hemost DOI: 10.1055/s-0043-1771270Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke in cancer patients. Novel biomarkers, including coagulation, platelet and endothelial markers, cell-free DNA, and extracellular vesicles are being investigated for their potentia...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2023 Category: Hematology Authors: Costamagna, Gianluca Navi, Babak B. Beyeler, Morin Hottinger, Andreas F. Alberio, Lorenzo Michel, Patrik Tags: Review Article Source Type: research

Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years
Semin Thromb Hemost DOI: 10.1055/s-0043-1769013Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially...
Source: Seminars in Thrombosis and Hemostasis - May 18, 2023 Category: Hematology Authors: Tufano, Antonella Brenner, Benjamin Tags: Review Article Source Type: research

Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research

PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Adelborg, F.S. Troelsen, C.H. Fuglsang, E. Horv áth-Puhó, H.T. Sørensen Tags: Posters Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study
Pulmonary embolism (PE) ranks as the third most common cardiovascular death after coronary artery disease and stroke [1] and, the second leading cause of death after cancer among cancer patients [2]. Acute Kidney Injury (AKI), defined as an abrupt decrease in kidney function, is associated with adverse short-term and long-term outcomes even in the case of mild and reversible AKI [3]. One-third of patients with PE develop AKI and are at increased risk for bleeding and mortality compared with patients without AKI [4].
Source: Thrombosis Research - January 14, 2021 Category: Hematology Authors: Martin Murgier, L éa Fouillet, Edouard Ollier, Adel Merah, Nathalie Moulin, Sandrine Accassat, Cécile Duvillard, Elodie De Magalhaes, Patrick Mismetti, Manuel Monreal, Laurent Bertoletti Tags: Letter to the Editors-in-Chief Source Type: research

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
ConclusionsIn comparison to VKA, DOACs were associated with a significant reduction of the rates of thromboembolic events and major bleeding complications in patients with AF and cancer. Further studies are needed to confirm our results.
Source: Journal of Thrombosis and Thrombolysis - October 12, 2020 Category: Hematology Source Type: research

Is there a role for low-dose DOACs as prophylaxis?
Authors: Cohen AT, Hunt BJ Abstract The direct oral anticoagulants (DOACs) have transformed the management of thrombotic disorders. Large clinical trials have demonstrated that DOACs can replace vitamin K antagonists (VKAs) in the 2 existing major indications for anticoagulation: the prevention of stroke in atrial fibrillation and the acute treatment and secondary prevention of venous thromboembolism (VTE); this literature is widely known. In this article, we will concentrate on the less well-discussed benefits of the use of DOACs-using low doses as primary and secondary prophylaxis in both venous and arterial thro...
Source: Hematology ASH Education Program - December 7, 2019 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
CONCLUSION:  In AF patients with malignancy, NOACs appear at least as effective as VKAs in preventing thrombotic events and reduce intracranial bleeding. NOACs may represent a valid and more practical alternative to VKAs in this setting of high-risk patients. PMID: 31785599 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 29, 2019 Category: Hematology Authors: Cavallari I, Verolino G, Romano S, Patti G Tags: Thromb Haemost Source Type: research

Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study.
CONCLUSION:  In this study, one in five patients discharged from an Italian IMU received prophylaxis for VTE. The perceived thrombotic risk is significantly related to the use of prophylaxis. PMID: 31634959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 20, 2019 Category: Hematology Authors: Squizzato A, Agnelli G, Campanini M, Dentali F, Agnelli F, Bonizzoni E, Franco A, Gallo A, Gussoni G, Nitti C, Triolo G, Valerio A, Ventrella F, Fontanella A, FADOI-NoTEVole Study Group Tags: Thromb Haemost Source Type: research

Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved. PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research

Feeling the Force: Measurements of Platelet Contraction and Their Diagnostic Implications
Semin Thromb Hemost DOI: 10.1055/s-0038-1676315In addition to the classical biological and biochemical framework, blood clots can also be considered as active biomaterials composed of dynamically contracting platelets, nascent polymeric fibrin that functions as a matrix scaffold, and entrapped blood cells. As platelets sense, rearrange, and apply forces to the surrounding microenvironment, they dramatically change the material properties of the nascent clot, increasing its stiffness by an order of magnitude. Hence, the mechanical properties of blood clots are intricately tied to the forces applied by individual platelets. ...
Source: Seminars in Thrombosis and Hemostasis - December 19, 2018 Category: Hematology Authors: Williams, Evelyn Kendall Oshinowo, Oluwamayokun Ravindran, Abhijit Lam, Wilbur A. Myers, David R. Tags: Review Article Source Type: research

Thromboembolism and bleeding in patients with cancer and mechanical heart valves
AbstractMechanical heart valves (MHV) require life-long anticoagulation with vitamin K antagonists (VKA), but anticoagulation management is complex in patients with cancer due to a high risk of thrombosis and bleeding. This is a retrospective, single-center study to assess anticoagulation management and thrombotic (stroke/valve thrombosis) and bleeding events in patients with active cancer and MHV. The incidence of thrombotic complications was compared to a control group (matched 1:1) of patients with MHV but without cancer. We included 48 patients, 60% of whom had aortic prostheses, 23% mitral prostheses and 17% both type...
Source: Journal of Thrombosis and Thrombolysis - December 17, 2018 Category: Hematology Source Type: research